An independent study commissioned by startup iSpecimen has found that 83 percent of patients would allow the leftovers of their blood samples, drawn for clinical purposes, to be used for medical research.
Boston startup iSpecimen is a next-gen, cloud-based biobank - helping researchers source samples remotely, direct from the hospital. "They can generate high margin revenue off of yesterday's garbage," CEO Christopher Ianelli said.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Boston startup iSpecimen‘s primary dealings are with excreta – the company supplies, on-demand, human biospecimens like blood, urine and feces to researchers. iSpecimen uses de-identified medical records to seek out specific patient characteristics that a researcher is looking for. It then instructs its healthcare partners to pick and ship specimens like blood, urine and cerebrospinal fluid to the customer. ISpecimen just […]